Scientific Advisory Board
Dr. Mukund Chorghade is a serial entrepreneur, President and Chief Scientific Officer, THINQ Pharma / THINQ Discovery, and of Chorghade Enterprises. He is the Chief Scientific Officer of Chicago Discovery Solutions, and has had Adjunct Research Professor / Visiting Fellow / Scientists appointments at Harvard, MIT, Princeton, Cambridge, Caltech, Univ. of Chicago, Northwestern, Strathclyde and several other universities. Dr. Chorghade earned his B. Sc. and M. Sc. degrees from the University of Poona, and a Ph. D. in organic chemistry at Georgetown University. He completed postdoctoral appointments at the University of Virginia and Harvard University, visiting scientist appointments at University of British Columbia, College de France / Universite’ Louis Pasteur, Cambridge and Caltech and directed research groups at Dow Chemicals, Abbott Laboratories, CytoMed and Genzyme. A recipient of three “Scientist of the Year Awards”, he is an elected Fellow of the ACS, AAAS, AIC and RSC and has been a featured speaker in several national and international symposia. He was privileged to become an American Chemical Society member in 1982, was section chair for Brazoria (1990) and of Northeastern Section in 2007 and is currently on the Board of Directors of the Northeastern Section. He heads the Professional Services, Public Relations Committees of the section and is an active participant in the activities of the ACS Career Services / Professional Development at the national level. He is currently on the US National Committee for IUPAC. He is on the Scientific Advisory Board of several corporations / foundations. He has been honored by election as a Fellow to the Maharashtra, Andhra Pradesh and Telengana Academy of Sciences, Royal Society of Chemistry (Elected Fellow); New York Academy of Sciences; American Chemical Society (Elected Fellow), American Institute of Chemists (Elected Fellow); AAAS (Elected Fellow); Sigma Xi; Indian Society of Chemists and Biologists (Elected Fellow).
Atanas G. Atanasov
Prof. Atanasov is a senior researcher at Department of Pharmacognosy, University of Vienna, Austria, where he was actively involved in the execution of the Austrian national network “Drugs From Nature Targeting Inflammation” (DNTI), a collaborative research project which has been financed with >3 000 000 Euro from the Austrian Science Fund (FWF) to support the identification and characterization of plant-derived natural products counteracting inflammatory responses. Prof. Atanasov has also been appointed as a beneficiary member and actively contributed to the European Commission 7th Framework Program (FP7) network consortium “Good Practice in Traditional Chinese Medicine (GP-TCM)”. In recognition of his overall achievements, Prof. Atanasov has been awarded in 2012 with a “Focus of Excellence” distinction by the Faculty of Life Sciences, University of Vienna. In 2016, Prof. Atanasov accomplished his Habilitation in Pharmacognosy -Pharmaceutical Biology at the Department of Pharmacognosy (University of Vienna, Austria) and was appointed to act as a Department Head (Department of Molecular Biology) at the Institute of Genetics and Animal Breeding of the Polish Academy of Sciences (Jastrzebiec, Poland).
Philip Judson studied chemistry at the University of Manchester before working on the synthesis of novel herbicides and fungicides for Fisons Ltd at Chesterford Park Research Station near Saffron Walden. When computing started to come into use in chemistry he took an interest in knowledge-based computer systems and became Head of Chemical Information and Computing for Schering Agrochemicals Ltd. He was one of the founders of Lhasa Limited, a not-for-profit company specialising in knowledge-based expert systems in chemistry including the widely-used Derek, Meteor, and Zeneth systems for predicting chemical toxicity, metabolism, and chemical degradation. He continues to contribute to research and development work at Lhasa Limited in his role as Scientific Advisor. He developed and maintains software for chemical hazard classification and chemical safety data sheet management, Harmoneus and Prometheus, which are supplied by Hibiscus plc. He has published over fifty papers, posters, and book chapters. His book on the use of knowledge-based methods in chemistry and toxicology, “Knowledge-Based Expert Systems in Chemistry – Not Counting on Computers”, is currently the only one covering the use of reasoning in chemoinformatics and its history.
Johannes Kirchmair is Professor of Applied Bioinformatics at the Center for Bioinformatics, University of Hamburg, and Head of the Junior Research Group for Applied Cheminformatics and Molecular Design. He earned his PhD in Cheminformatics/Medicinal Chemistry from the University of Innsbruck in 2007. Johannes started his career as Application Scientist at Inte:Ligand, Vienna, and University Assistant at his Alma Mater. In 2010 he joined BASF (Ludwigshafen), where he was responsible for the computational optimization of new fungicide leads. He worked as a research associate at the Centre for Molecular Informatics, University of Cambridge (2010-2013), and as a principal investigator of a research project on drug metabolism prediction at ETH Zurich (2013-2014). His main research interests include the development and application of computational methods for the prediction of the bioactivity and metabolism of drugs and drug-like molecules, active ingredients in skin care products, agrochemicals and functional foods.
Dr. Barry Hardy Hardy is currently leading Douglas Connect and its team supporting the development of new integrating solutions in industrial safety assessment. An example application is that for integrated testing for skin sensitization available at DouglasConnect. He has coordinated the OpenTox project in predictive toxicology and the ToxBank infrastructure development project. He is currently President of the OpenTox Association, founded in 2015 as an international non-profit organisation promoting an open knowledge community approach to new methods in predictive toxicology. He recently led the infrastructure development for the IMI EBiSC stem cell banking project and the eNanoMapper project developing OpenTox solutions supporting nanotechnology safety assessment. New projects include leading OpenRiskNet, knowledge infrastructure development for ACEnano and Eu-ToxRisk and translation of research methods to industrial practice within ToxHQ. He has led the development of research and best practice activities in drug design and toxicology through founding the eCheminfo Community of Practice, InnovationWell and leading the Scientists Against Malaria project. Dr. Hardy obtained his Ph.D. in 1990 from Syracuse University working in computational science. He was a National Research Fellow at the FDA Center for Biologics and Evaluation, a Hitchings-Elion Fellow at Oxford University and CEO of Virtual Environments International. He was a pioneer in the 1990s in the development of Web technology applied to virtual scientific communities and conferences. He has developed technology solutions for internet-based communications, tutor-supported e-learning, laboratory automation systems, and computational science and informatics. In recent years he has also been active in the field of knowledge management as applied to supporting innovation, communities of practice, and collaboration.
Professor Robert Preissner obtained his diploma in Biophysics in 1988 from the Humboldt-University, Berlin. Until 1990 he worked as a research associate in the department of Biomathematics at the Academy of Sciences. When the Berlin Wall came down he joined the Institute of Crystallography, Department of Protein Crystallography at the Free University, Berlin. He received his PhD with a thesis on the relations between sequences and structures of proteins. Since 1993 he has held a research position at the Institute of Biochemistry, Charite-University Medicine Berlin. Since 2001 he has been a group leader at the Berlin Center for Genome Based Bioinformatics, Charite. His interdisciplinary research group focuses on multiple research topics in fields of bio/cheminformatics and personalized medicine, with the primary interests: understanding the structure, function and interaction of chemicals with therapeutic and off-targets. By applying a wide range of cheminformatics methods including chemical similarity approaches, molecular docking and simulations, they propose hypotheses to answer complex questions in drug discovery. They also develop in silico models to predict the target landscape of small molecules relevant in cancer research and for other pharmaceutically relevant endpoints (cardiotoxicity, hepatotoxicity etc.). With an aim to serve the research community, they developed several bio- and cheminformatics databases and web servers (listed below). Using their knowledge base and toolchain, they analyze healthcare data in order to propose recommendations to improve decision making in clinical practices, and develop computational methods to contribute to the state-of-the-art in the research field.